November 17, 2026
Lilly agrees to acquire Calytrix Bio for $1.5bn
Eli Lilly has agreed to acquire Calytrix Bio in a deal valued at up to $1.5bn to advance an investigational biparatopic antibody targeting mutant calreticulin (mCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







